Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2)

Brief description of study

The purpose of the study is to evaluate the biological activity of systemic therapies in people with Neurofibromatosis type 2 (NF2) related tumors. Tumor types eligible for inclusion upon progression will include vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas. We want to assess safety and tolerability of Brigatinib to determine how subjects respond to the study agent. The study drug Brigatinib is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.


Clinical Study Identifier: s20-00223
ClinicalTrials.gov Identifier: NCT04374305
Principal Investigator: Kaleb H. Yohay.
Other Investigators: Devorah Segal, Sharon L Gardner, Erin Byrd, Jessica Clymer.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.